Next Article in Journal
Acceptability of a Mobile-Health Living Kidney Donor Advocacy Program for Black Wait-Listed Patients
Next Article in Special Issue
The Impact of the COVID-19 Pandemic on Tourists’ WTP: Using the Contingent Valuation Method
Previous Article in Journal
Active Coping and Anxiety Symptoms during the COVID-19 Pandemic in Spanish Adults
Previous Article in Special Issue
Comparison of SARS-CoV-2 Detection by Rapid Antigen and by Three Commercial RT-qPCR Tests: A Study from Martin University Hospital in Slovakia
 
 
Opinion
Peer-Review Record

Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond

Int. J. Environ. Res. Public Health 2021, 18(16), 8242; https://doi.org/10.3390/ijerph18168242
by Michał Nowicki 1,*, Stanisława Bazan-Socha 2, Mariusz Kłopotowski 3, Beata Błażejewska-Hyżorek 4, Mariusz Kusztal 5, Krzysztof Pawlaczyk 6,7, Jarosław Sławek 8, Andrzej Oko 7 and Zofia Oko-Sarnowska 9,† on behalf of the Polish Fabry Disease Collaborative Group
Reviewer 1: Anonymous
Reviewer 2:
Int. J. Environ. Res. Public Health 2021, 18(16), 8242; https://doi.org/10.3390/ijerph18168242
Submission received: 24 June 2021 / Revised: 30 July 2021 / Accepted: 2 August 2021 / Published: 4 August 2021

Round 1

Reviewer 1 Report

1) The paragraph (r. 67-71) is incomprehensible. It is advisable to rewrite.

2) Table 1. Availability of home-based ERT prog. in various countries - the table is weak. Could you describe yoursource of information in every country you mentioned? And - would it be possible to add the information - % of ERT home - based and/ or number of treated pts in the country vs home based treatment? 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The authors give a good review of the status of home treatment for Fabry disease in different countries. It is well structured and reflects the advantages and possible disadvantages that may arise. It demonstrates with many references that in general this type of strategy benefits the patient, improves the quality of life without losing contact with the medical team using different digital solutions and is an important procedure in risk prevention in this pandemic period.

A reference to the coordination phase with the hospital pharmacy team is missing. The home administration procedure requires preparation conditions and a traceability monitoring protocol to ensure that the drug to be infused has followed a controlled process of preparation, temperature and time conditions, which requires an adequate protocol, since patients are generally very far from the central Pharmacy and logistical problems can be solved.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop